CRSP FY2024 EPS Reduced by Brookline Capital Management

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Brookline Capital Management reduced their FY2024 earnings per share estimates for CRISPR Therapeutics in a note issued to investors on Tuesday, November 5th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($5.18) for the year, down from their prior estimate of ($4.88). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.57) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics' Q4 2024 earnings at ($1.36) EPS, FY2025 earnings at ($5.76) EPS, FY2026 earnings at $8.07 EPS, FY2027 earnings at $11.96 EPS and FY2028 earnings at $26.00 EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the previous year, the business posted ($1.41) earnings per share.

Other analysts also recently issued reports about the stock. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating on the stock in a research report on Tuesday, August 6th. StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a report on Thursday. Chardan Capital decreased their price objective on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a "buy" rating for the company in a report on Tuesday, August 6th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday. Finally, Truist Financial cut their target price on CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, August 12th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Hold" and an average target price of $74.94.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded down $0.26 on Friday, reaching $51.62. 1,304,947 shares of the company were exchanged, compared to its average volume of 1,455,758. The firm has a market cap of $4.39 billion, a price-to-earnings ratio of -16.06 and a beta of 1.67. CRISPR Therapeutics has a 1-year low of $43.42 and a 1-year high of $91.10. The company's 50-day moving average is $47.38 and its two-hundred day moving average is $52.24.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, General Counsel James R. Kasinger sold 1,089 shares of the business's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the firm's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers grew its stake in shares of CRISPR Therapeutics by 451.3% during the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company's stock worth $2,324,000 after buying an additional 27,915 shares during the last quarter. CWM LLC increased its position in shares of CRISPR Therapeutics by 11,871.1% during the second quarter. CWM LLC now owns 22,386 shares of the company's stock valued at $1,209,000 after acquiring an additional 22,199 shares in the last quarter. Capital Advisors Inc. OK raised its stake in shares of CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company's stock worth $14,122,000 after purchasing an additional 22,583 shares during the last quarter. Granite Bay Wealth Management LLC bought a new position in shares of CRISPR Therapeutics during the 2nd quarter valued at $2,375,000. Finally, Krilogy Financial LLC lifted its holdings in CRISPR Therapeutics by 92.9% in the second quarter. Krilogy Financial LLC now owns 20,872 shares of the company's stock valued at $1,127,000 after acquiring an additional 10,050 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.